170 related articles for article (PubMed ID: 30796167)
21. Feasibility of experimental BT4C glioma models for somatostatin receptor 2-targeted therapies.
Kiviniemi A; Gardberg M; Autio A; Li XG; Heuser VD; Liljenbäck H; Käkelä M; Sipilä H; Kurkipuro J; Ylä-Herttuala S; Knuuti J; Minn H; Roivainen A
Acta Oncol; 2014 Aug; 53(8):1125-34. PubMed ID: 24957558
[TBL] [Abstract][Full Text] [Related]
22. Performance of 177Lu-DOTATATE-based peptide receptor radionuclide therapy in metastatic gastroenteropancreatic neuroendocrine tumor: a multiparametric response evaluation correlating with primary tumor site, tumor proliferation index, and dual tracer imaging characteristics.
Thapa P; Ranade R; Ostwal V; Shrikhande SV; Goel M; Basu S
Nucl Med Commun; 2016 Oct; 37(10):1030-7. PubMed ID: 27243215
[TBL] [Abstract][Full Text] [Related]
23. Direct comparison of (68)Ga-DOTA-TOC and (18)F-FDG PET/CT in the follow-up of patients with neuroendocrine tumour treated with the first full peptide receptor radionuclide therapy cycle.
Nilica B; Waitz D; Stevanovic V; Uprimny C; Kendler D; Buxbaum S; Warwitz B; Gerardo L; Henninger B; Virgolini I; Rodrigues M
Eur J Nucl Med Mol Imaging; 2016 Aug; 43(9):1585-92. PubMed ID: 26922350
[TBL] [Abstract][Full Text] [Related]
24. Receptor radionuclide targeting for neuroendocrine tumors (NET) diagnostic and therapy.
Vija L; Dierickx L; Courbon F
Ann Endocrinol (Paris); 2019 Jun; 80(3):166-171. PubMed ID: 31053248
[TBL] [Abstract][Full Text] [Related]
25. Valproic acid induces NET cell growth arrest and enhances tumor suppression of the receptor-targeted peptide-drug conjugate via activating somatostatin receptor type II.
Sun L; Qian Q; Sun G; Mackey LV; Fuselier JA; Coy DH; Yu CY
J Drug Target; 2016; 24(2):169-77. PubMed ID: 26211366
[TBL] [Abstract][Full Text] [Related]
26. The prognostic and predictive value of sstr
Brunner P; Jörg AC; Glatz K; Bubendorf L; Radojewski P; Umlauft M; Marincek N; Spanjol PM; Krause T; Dumont RA; Maecke HR; Müller-Brand J; Briel M; Schmitt A; Perren A; Walter MA
Eur J Nucl Med Mol Imaging; 2017 Mar; 44(3):468-475. PubMed ID: 27539020
[TBL] [Abstract][Full Text] [Related]
27. DNA-PKcs inhibitors sensitize neuroendocrine tumor cells to peptide receptor radionuclide therapy
Reuvers TGA; Verkaik NS; Stuurman D; de Ridder C; Groningen MCC; de Blois E; Nonnekens J
Theranostics; 2023; 13(10):3117-3130. PubMed ID: 37351169
[No Abstract] [Full Text] [Related]
28. Patient-specific dosimetry in peptide receptor radionuclide therapy: a clinical review.
Chalkia MT; Stefanoyiannis AP; Chatziioannou SN; Round WH; Efstathopoulos EP; Nikiforidis GC
Australas Phys Eng Sci Med; 2015 Mar; 38(1):7-22. PubMed ID: 25427548
[TBL] [Abstract][Full Text] [Related]
29. 68Ga-DOTATOC and FDG PET Imaging of Preclinical Neuroblastoma Models.
Provost C; Prignon A; Cazes A; Combaret V; Delattre O; Janoueix-Lerosey I; Montravers F; Talbot JN
Anticancer Res; 2016 Sep; 36(9):4459-66. PubMed ID: 27630282
[TBL] [Abstract][Full Text] [Related]
30. Achieving objective response in treatment of non-resectable neuroendocrine tumors does not predict longer time to progression compared to achieving stable disease.
Thiis-Evensen E; Poole AC; Nguyen HT; Sponheim J
BMC Cancer; 2020 May; 20(1):466. PubMed ID: 32448245
[TBL] [Abstract][Full Text] [Related]
31. Sensitivity Comparison of
Nicolas GP; Schreiter N; Kaul F; Uiters J; Bouterfa H; Kaufmann J; Erlanger TE; Cathomas R; Christ E; Fani M; Wild D
J Nucl Med; 2018 Jun; 59(6):915-921. PubMed ID: 29191855
[TBL] [Abstract][Full Text] [Related]
32. Patient selection for personalized peptide receptor radionuclide therapy using Ga-68 somatostatin receptor PET/CT.
Kulkarni HR; Baum RP
PET Clin; 2014 Jan; 9(1):83-90. PubMed ID: 25029937
[TBL] [Abstract][Full Text] [Related]
33. Association of somatostatin receptor 2 immunohistochemical expression with [111In]-DTPA octreotide scintigraphy and [68Ga]-DOTATOC PET/CT in neuroendocrine tumors.
Müssig K; Oksüz MO; Dudziak K; Ueberberg B; Wehrmann M; Horger M; Schulz S; Häring HU; Pfannenberg C; Bares R; Gallwitz B; Petersenn S
Horm Metab Res; 2010 Jul; 42(8):599-606. PubMed ID: 20422506
[TBL] [Abstract][Full Text] [Related]
34. Dosimetric analysis of patients with gastro entero pancreatic neuroendocrine tumors (NETs) treated with PRCRT (peptide receptor chemo radionuclide therapy) using Lu-177 DOTATATE and capecitabine/temozolomide (CAP/TEM).
Thakral P; Sen I; Pant V; Gupta SK; Dureja S; Kumari J; Kumar S; Un P; Malasani V
Br J Radiol; 2018 Nov; 91(1091):20170172. PubMed ID: 30028180
[TBL] [Abstract][Full Text] [Related]
35. Yttrium-90 DOTATOC therapy in GEP-NET and other SST2 expressing tumors: a selected review.
Nisa L; Savelli G; Giubbini R
Ann Nucl Med; 2011 Feb; 25(2):75-85. PubMed ID: 21107762
[TBL] [Abstract][Full Text] [Related]
36. Does the pretherapeutic tumor SUV in 68Ga DOTATOC PET predict the absorbed dose of 177Lu octreotate?
Ezziddin S; Lohmar J; Yong-Hing CJ; Sabet A; Ahmadzadehfar H; Kukuk G; Biersack HJ; Guhlke S; Reichmann K
Clin Nucl Med; 2012 Jun; 37(6):e141-7. PubMed ID: 22614212
[TBL] [Abstract][Full Text] [Related]
37. Use of radioactive substances in diagnosis and treatment of neuroendocrine tumors.
Kjaer A; Knigge U
Scand J Gastroenterol; 2015 Jun; 50(6):740-7. PubMed ID: 25959100
[TBL] [Abstract][Full Text] [Related]
38. Is There an Additional Value of Using Somatostatin Receptor Subtype 2a Immunohistochemistry Compared to Somatostatin Receptor Scintigraphy Uptake in Predicting Gastroenteropancreatic Neuroendocrine Tumor Response?
van Adrichem RC; Kamp K; van Deurzen CH; Biermann K; Feelders RA; Franssen GJ; Kwekkeboom DJ; Hofland LJ; de Herder WW
Neuroendocrinology; 2016; 103(5):560-6. PubMed ID: 26536001
[TBL] [Abstract][Full Text] [Related]
39. Somatostatin Analogues in the Treatment of Neuroendocrine Tumors: Past, Present and Future.
Stueven AK; Kayser A; Wetz C; Amthauer H; Wree A; Tacke F; Wiedenmann B; Roderburg C; Jann H
Int J Mol Sci; 2019 Jun; 20(12):. PubMed ID: 31234481
[TBL] [Abstract][Full Text] [Related]
40. Peptide receptor radionuclide therapy with Y-DOTATOC and (177)Lu-DOTATOC in advanced neuroendocrine tumors: results from a Danish cohort treated in Switzerland.
Pfeifer AK; Gregersen T; Grønbæk H; Hansen CP; Müller-Brand J; Herskind Bruun K; Krogh K; Kjær A; Knigge U
Neuroendocrinology; 2011; 93(3):189-96. PubMed ID: 21335949
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
